NOVARTIS

KESIMPTA - Downloadable resources - HCP

Prescribing information

Image

Image

KESIMPTA®▼(ofatumumab) downloadable resources

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.[1]

This selection of resources is designed for healthcare professionals to support patients with relapsing forms of multiple sclerosis (RMS) throughout their KESIMPTA journey.

You can download these materials and share them with your healthcare team. There is a separate tab for resources which can be shared with patients. Please do not share this web page with patients; instead, please direct them to the patient portal where they can access

these resources.

- Resources for HCPs

- Resources for patients

Image



KESIMPTA DEMONSTRATION PEN KIT

PDF
Download
Image

TREATMENT INITIATION CHECKLIST

PDF
Download

- Resources for HCPs

- Resources for patients

Image


Kesimpta▼
ofatumumab
Getting to know
KESIMPTA® (ofatumumab)
This booklet is intended for patients who have been prescribed ofatumumab.
Reporting of side effects
If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack.
▼The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please see www.mhra.gov.uk/yellowcard (UK) for instructions on how to report side effects.
This leaflet has been developed and funded by Novartis Pharmaceuticals UK Limited.
This booklet should not replace the information shared to you by your nurse or pharmacist or within the packaging information.
NOVARTIS

PATIENT WELCOME BOOKLET

PDF
Download

Reference

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

Image

Safety profile

UK | January 2025 | 443408

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
